• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M

March 10, 2021 By Sean Whooley

Takeda Maverick TherapeuticsTakeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million.

Osaka, Japan-based Takeda exercised its option to acquire Maverick and its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages.

Following the closing of the deal, Maverick employees will join Takeda’s research & development team, according to a news release.

Brisbane, Calif.-based Maverick’s Cobra platform is designed to target a broad range of solid tumors with highly specific and potent activity while limiting toxicities in normal tissues. The protein-based therapies are engineered to exploit the tumor microenvironment, killing only at the tumor site and sparing damage to patients’ healthy tissues.

The deal follows a multi-year collaboration between Takeda and Maverick to develop conditionally active T-cell engager therapies. The collaboration included an equity stake in Maverick for Takeda and an exclusive right to purchase the company after five years.

Takeda exercised the option to buy Maverick for a pre-negotiated, upfront payment, as well as potential development and regulatory milestones, that altogether totals $525 million, subject to certain adjustments, including for Takeda’s equity stake and Maverick’s debt. The deal is expected to be finalized in the first quarter of Takeda’s fiscal 2021.

“Collaboration is paramount to our R&D strategy and our pursuit of novel approaches to treat cancer,” Takeda oncology therapeutic area unit head Chris Arendt said in the release. “By supporting pioneers like Maverick working in emerging areas of science, we can share expertise, resources and risk to bring transformational new therapies to patients faster. Maverick’s cutting-edge Cobra platform is an exciting addition to our oncology portfolio that provides a novel conditional bioengineering approach to advance redirected immunotherapies against solid tumors.”

Maverick Therapeutics CEO James Scibetta added that patients will benefit from the added resources and experience Takeda will bring to developing Cobra-derived therapies.

“Takeda has been an excellent partner since Maverick’s inception, venerating our independence through a period marked by rapid innovation, providing actionable consultation, and providing direct cell line development and manufacturing support through the COVID-19 pandemic to keep us on our aggressive schedule,” Scibetta said.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Mergers & Acquisitions, Oncology, Pharmaceuticals Tagged With: Maverick Therapeutics, Takeda Pharmaceutical Co

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS